DYNACIRC CR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Jun 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DYNACIRC CR is an extended-release oral tablet formulation of a small-molecule antihypertensive approved by GSK in 1994. The product treats hypertension through a calcium channel blocking mechanism. It is designed for chronic oral administration in patients requiring sustained blood pressure control.
LOE Approaching
As LOE approaches, commercial teams are downsizing; career opportunities focus on managed decline and generic transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DYNACIRC CR offers limited career growth opportunities due to its LOE-approaching status and minimal linked job openings. Working on this product typically involves managing decline, supporting generic transition, and maintaining relationships with healthcare providers in a shrinking market.
Brand ManagerField Sales Representative
Worked on DYNACIRC CR at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.